RxDoctor Payments Data

Ashish Gupta, MD

Cardiovascular Disease · Winter Park, FLNPI 1265521470

Payments from drug & device makers

$479,554in general payments, 2019–2025

Across 933 payments — averaging $513.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$203K
  • Boehringer Ingelheim$62K
  • Philips North America LLC$53K
  • AstraZeneca$38K
  • Endologix LLC$38K
  • Sanofi US Services Inc.$13K
  • plus $73K from 53 others

What the payments were for

  • Consulting fees$4,7501%
  • Speaking & faculty fees$268,63885%
  • Travel & lodging$15,6845%
  • Food & beverage$28,1669%
  • Education$1560%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson232$203,136
Boehringer Ingelheim62$61,650
Philips North America LLC42$53,082
AstraZeneca(2 entities)11$37,934
Endologix LLC25$37,538
Sanofi US Services Inc.4$13,100
Lilly USA, LLC5$9,348
Scpharmaceuticals Inc.6$8,665
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)6$8,626
Cook Medical LLC59$6,267
Boehringer Ingelheim Pharma GmbH & Co.kg2$6,099
Ionis Pharmaceuticals, Inc.3$4,939
Boehringer Ingelheim International GmbH52$4,420
M.a. Med Alliance S.A.2$2,958
Cardiovascular Systems Inc.6$2,820
Bard Peripheral Vascular, Inc.29$2,274
Reflow Medical Inc3$2,022
Penumbra, Inc.9$1,637
Medtronic(2 entities)24$1,568
Novartis65$1,043
Cvrx, Inc.11$1,004
Actelion Pharmaceuticals US, Inc.12$857
E.r. Squibb & Sons, L.L.C.55$765
Amgen24$730
Abiomed5$697
Merck22$608
Novo Nordisk8$528
Abbott8$522
Impulse Dynamics (USA) Inc.7$504
Sanofi-aventis U.S. LLC21$400
Boston Scientific8$375
Janssen Scientific Affairs, LLC4$370
Cordis US CORP.8$365
Esperion Therapeutics, Inc.14$324
Amarin Pharma, Inc.8$261
Heartflow, Inc.3$226
Pfizer12$219
Inari Medical, Inc.1$200
Bayer10$195
Asahi Intecc USA, Inc.1$157
Shockwave Medical, Inc2$148
Cardinal Health 200 LLC6$136
Smith+Nephew1$115
Siemens Medical Solutions USA, Inc.1$111
Celonova Biosciences, Inc.1$100
Tactile Systems Technology Inc6$83
Alnylam Pharmaceuticals Inc.3$73
W. L. Gore & Associates, Inc.5$69
Elutia, Inc.6$60
Atricure, Inc.2$33
Insmed, Inc.1$33
Daiichi Sankyo Inc.2$28
Veryan Medical Incorporated1$27
Arbor Pharmaceuticals, Inc.2$25
United Therapeutics Corporation1$22
Kowa Pharmaceuticals America, Inc.1$18
Regeneron Healthcare Solutions, Inc.1$17
Edwards Lifesciences1$15
Lexicon Pharmaceuticals, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$479,554 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$952,550
Medicare patients
830
Services billed
15,405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban274$218,909
EliquisApixaban136$103,412
MounjaroTirzepatide71$73,138
EntrestoSacubitril/Valsartan81$65,206
JardianceEmpagliflozin82$59,932
OzempicSemaglutide64$59,131
Repatha SureclickEvolocumab75$51,301
FarxigaDapagliflozin Propanediol76$45,114
VascepaIcosapent Ethyl34$16,571
Ranolazine ErRanolazine36$3,280
ClopidogrelClopidogrel Bisulfate168$2,027
Metoprolol Succinate149$1,992
Losartan Potassium198$1,883
Bumetanide40$1,726
Cilostazol93$1,654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$203,136$218,909274 claims
PfizerEliquis$219$103,412136 claims
Lilly USA, LLCMounjaro$9,348$73,13871 claims
NovartisEntresto$1,043$65,20681 claims
Boehringer IngelheimJardiance$61,650$59,93282 claims
Novo NordiskOzempic$528$59,13164 claims
AstraZenecaFarxiga$37,934$45,11476 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Winter Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →